$4.21 -0.2 -4.1%
Last Trade - 26/02/21
| Market Cap | £28.2m |
| Enterprise Value | £-8.51m |
| Revenue | £n/a |
| Position in Universe | 5654th / 6715 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | March 16, 2004 |
| Public Since | July 21, 2000 |
| No. of Shareholders: | 13 |
| No. of Employees: | 9 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Capital Market |
| Shares in Issue | 9,321,470 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 10170 Church Ranch Way Suite 100, WESTMINSTER, 80021, United States |
| Web | http://arcabio.com/ |
| Phone | +1 720 9402100 |
| Contact | () |
| Auditors | KPMG LLP |
As of 26/02/21, shares in ARCA Biopharma Inc are trading at $4.21, giving the company a market capitalisation of £28.2m. This share price information is delayed by 15 minutes.
Shares in ARCA Biopharma Inc are currently trading at $4.21 and the price has moved by 29.34% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the ARCA Biopharma Inc price has moved by -0.22% over the past year.
Of the analysts with advisory recommendations for ARCA Biopharma Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for ARCA Biopharma Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
ARCA Biopharma Inc is scheduled to issue upcoming financial results on the following dates:
ARCA Biopharma Inc does not currently pay a dividend.
ARCA Biopharma Inc does not currently pay a dividend.
ARCA Biopharma Inc does not currently pay a dividend.
To buy shares in ARCA Biopharma Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in ARCA Biopharma Inc are currently trading at $4.21, giving the company a market capitalisation of £28.2m.
Here are the trading details for ARCA Biopharma Inc:
Based on an overall assessment of its quality, value and momentum, ARCA Biopharma Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in ARCA Biopharma Inc are currently priced at $4.21. At that level they are trading at 66.27% discount to the analyst consensus target price of 0.00.
Analysts covering ARCA Biopharma Inc currently have a consensus Earnings Per Share (EPS) forecast of -9.59 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ARCA Biopharma Inc. Over the past six months, the relative strength of its shares against the market has been -22.88%. At the current price of $4.21, shares in ARCA Biopharma Inc are trading at -19.97% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for ARCA Biopharma Inc.
ARCA Biopharma Inc's management team is headed by:
Here are the top five shareholders of ARCA Biopharma Inc based on the size of their shareholding:
